On July 10, 2018, with the support of the team led by our senior partner Wu Zetao as presenting attorneys, Henan Longdu Pharmaceutical Co., Ltd. (short name Longdu Pharmaceutical, stock code 872918 ) obtained a consent to its “Listing in Share Transfer System”([2018] No. 2423) and successfully listed on the National Equities Exchange and Quotations.

The main business of Longdu Pharmaceutical is production and sales of Chinese traditional patent medicine, and it has formed a product system dominated by Yuntongding Jiaonang. Yuntongding Jiaonang is exclusively produced in China, and its intellectual property rights is fully owned by Longdu Pharmaceutical, who has obtained a national invention patent in connection with it on December 10, 2008. Yuntongding Jiaonang has been selected into the catalogues of medicines covered by medical insurance of Henan Province, Hunan Province, Yunnan Province, Inner Mongolia Autonomous Region and Guangxi Zhuang Autonomous Region, and has been included into the lists of essential medicines in Henan, Hunan, Yunnan and Guangxi.

The team of Wu Zetao has extensive experience in practicing in the capital markets and may deliver distinctive outcome in the capital markets and in the dispute resolution involving the capital market. His team members, with their own practice advantages, provide clients with legal services throughout the whole course of NEEQ listing in a diligent, responsible, professional and rigorous way, and are highly recognized and appreciated by clients.